Chinese drug maker Shenzhen Hepalink Pharmaceutical plans to invest US$60 million in TPG Biotechnology Partners V, L.P., which mainly targets biomedical technology and life science companies, the company announced in a statement (in Chinese). In December 2014, Shenzhen Hepalink Pharmaceutical committed US$22 million to TPG Capital's previous biotech fund, TPG Biotechnology Partners IV, L.P. TPG […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.